Extending Natures Leads: The Anticancer Agent Ellipticine
Abstract
The natural plant product ellipticine was isolated in 1959 from the Australian evergreen tree of the Apocynaceae family. This compound was found to be an extremely promising anticancer drug. The planar polycyclic structure was found to interact with DNA through intercalation, exhibiting a high DNA binding affinity (10(6) M(-1)). The presence of protonatable ring nitrogens distinguished ellipticine from other simple intercalators. Both monocationic and uncharged species were found to be present under physiological conditions. The positive charge stabilized the binding of ellipticine to nucleic acids, while the more lipophilic uncharged compound was shown to readily penetrate membrane barriers. The structural nature of these compounds offers a plausible basis for the implication of multiple modes of action, including DNA binding, interactions with membrane barriers, oxidative bioactivation and modification of enzyme function; most notably that of topoisomerase II and telomerase. Pharmacologically, a number of toxic side effects have been shown to be problematic, but the amenability of ellipticine towards systematic structural modification has permitted the extensive application of rational drug design. A number of successful ellipticine analogs have been designed and synthesized with improved toxicities and anticancer activities. More recently the synthetic focus has broadened to include the design of hybrid compounds, as well as drug delivery conjugates. Considerable research efforts have been directed towards gaining a greater understanding of the mechanism of action of these drugs that will aid further in the optimization of drug design.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The suboptimal murine efficacy of ellipticine may be attributed to inadequate pharmacokinetic parameters of ellipticine.
“This outcome may be attributed to the inadequate pharmacokinetic parameters of ellipticine52”
From Impairing the interaction between Erg11 and cytochrome P450 reductase Ncp1 enhances azoles’ antifungal activities (2025) · cites this paper as [52]
Cited by
Sorted by citations
Current strategies to target p53 in cancer
Chen, F., Wang, W., & El‐Deiry, W. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.031 · Cited by 158 · see citing works
“However, extensive attempts have been made to systematically optimize EPC structure [53,54].”
Anthracyclines and ellipticines as DNA-damaging anticancer drugs: Recent advances
Kizek, R., Adam, V., Hraběta, J., Eckschlager, T., Smutný, S., Burda, J. V., Frei, E., & Stiborová, M. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.07.006 · Cited by 149 · see citing works
“…lymphomas, colon adenocarcinoma, lung carcinoma, diverse brain tumors, osteosarcoma, breast cancer and neuroblastomas, which were killed at concentrations ranging from 10−10 to 10−6 M (for an overview, see Arguello et al., 1998; Garbett & Graves, 2004; Stiborova et al., 2006b; Tian et al., 2008).”
Eissa, I. H., El‐Naggar, A. M., & El-Hashash, M. A. A. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.006 · Cited by 143 · see citing works
Attenuation of Nonsense-Mediated mRNA Decay Enhances In Vivo Nonsense Suppression
Keeling, K. M., Wang, D., Dai, Y., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0060478 · Cited by 120 · see citing works
“In contrast, ellipticine, an antineoplastic compound [33] that is structurally related to NMDI-1 (Figure S1B), did not inhibit NMD.”
Towards natural mimetics of metformin and rapamycin
Aliper, A. M., Jellen, L. C., Cortese, F., Artemov, A. V., Karpinsky‐Semper, D., Moskalev, A., Swick, A. G., & Zhavoronkov, A. A. (2017) · Aging · doi:10.18632/aging.101319 · Cited by 112 · see citing works
“Overall, the most remarkable aspect of the metformin results was that, like metformin, several of the compounds scoring high in similarity exhibit glucoselowering properties (withaferin A [121], umbelliferone [122], and allantoin [107,108]) or anti-inflammatory effects (glucosamine [111,112] and cardamonin [113]) in p…”
BackgroundResultRestoration of p53 to limit tumor growth
Wang, W., & El‐Deiry, W. S. (2008) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3282f31d6f · Cited by 105 · see citing works
Wink, M. (2007) · The Alkaloids. Chemistry and biology/The alkaloids. Chemistry and biology · doi:10.1016/s1099-4831(07)64001-2 · Cited by 96 · see citing works
Fung, S., Yang, H. Y., Bhola, P. T., Sadatmousavi, P., Muzar, E., Liu, M., & Chen, P. (2008) · Advanced Functional Materials · doi:10.1002/adfm.200800860 · Cited by 94 · see citing works
Small molecule agents targeting the p53‐MDM2 pathway for cancer therapy
Wang, W., & Hu, Y. (2011) · Medicinal Research Reviews · doi:10.1002/med.20236 · Cited by 87 · see citing works
“3), a potent anticancer agent found in the Australian evergreen tree of the Apocynaceae family, is associated with a wide range of anti-tumor effects.(82,83) Peng et al.”
BackgroundEllipticine cytotoxicity to cancer cell lines - a comparative study
Stiborová, M., Poljaková, J., Martínková, E., et al. (2011) · Interdisciplinary Toxicology · doi:10.2478/v10102-011-0017-7 · Cited by 81 · see citing works
“In the case of ellipticine, it has been suggested that the prevalent DNA-mediated mechanisms of its antitumor, mutagenic and cytotoxic activities are (i) intercalation into DNA and (ii) inhibition of DNA topoisomerase II activity (Auclair, 1987; Garbett & Graves, 2004; Stiborová et al., 2006; 2011).”
BackgroundAl‐Trawneh, S. A., Zahra, J. A., Kamal, M. R., et al. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.06.098 · Cited by 78 · see citing works
Kim, J. S., Rhee, H., Park, H. J., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.02.049 · Cited by 76 · see citing works
Çetinkol, Ö. P., & Hud, N. V. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn977 · Cited by 74 · see citing works
“While interesting with regard to the shapespecificity hypothesis, this molecule is not selective for poly(A) over Watson–Crick duplexes (36).”
BackgroundHasanzade, Z., & Raissi, . (2018) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2018.01.159 · Cited by 71 · see citing works
DNA intercalators as anticancer agents
Venugopal, S., Sharma, V., Mehra, A., et al. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14116 · Cited by 71 · see citing works
“Some of the commercially available DNA intercalators are given in Figure 2 (El- Helby et al., 2020, Garbett & Graves, 2004).”
BackgroundKuo, Y.-C., Kuo, P., Hsu, Y., Cho, C.-Y., & Lin, C. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.10.041 · Cited by 71 · see citing works
Andrews, W. J., Panova, T. B., Normand, C., Gadal, O., Tikhonova, I. G., & Panov, K. I. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.411611 · Cited by 68 · see citing works
Stiborová, M., Eckschlager, T., Poljaková, J., Hraběta, J., Adam, V., Kizek, R., & Frei, E. (2012) · Current Medicinal Chemistry · doi:10.2174/092986712802884286 · Cited by 68 · see citing works
“The predominant mechanisms of the biological effects of ellipticine were suggested to be (1) intercalation into DNA [197, 198] and (2) inhibition of topoisomerase II [194, 197, 198].”
BackgroundCarbazole Derivatives as Potential Antimicrobial Agents
Patil, S. A., Patil, S. A., Blé-González, E. A., et al. (2022) · Molecules · doi:10.3390/molecules27196575 · Cited by 65 · see citing works
“It was extracted from the leaves of Ochrosia elliptica and is considered to be one of the initial leading therapeutic carbazole analogs for the treatment of cancer [21].”
BackgroundPoljaková, J., Eckschlager, T., Hraběta, J., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.01.021 · Cited by 65 · see citing works
“their metabolic capacity, because of the general chemical properties of this drug and its affinity to DNA and topoisomerase II protein [4,9,45].”
BackgroundStiborová, M., Rupertová, M., & Frei, E. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.05.016 · Cited by 62 · see citing works
“[31,47–49], and (iii) to cause the initiation of the mitochondrial apoptosis pathway [30,31,47,48].”
BackgroundSynthesis and evaluation of novel ellipticines as potential anti-cancer agents
Deane, F. M., O’Sullivan, E. C., Maguire, A. R., et al. (2013) · Organic & Biomolecular Chemistry · doi:10.1039/c2ob27186a · Cited by 59 · see citing works
Bawa, R., Fung, S., Shiozaki, A., et al. (2011) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2011.08.007 · Cited by 59 · see citing works
Structural and Functional Basis for Therapeutic Modulation of p53 Signaling
Bassett, E. A., Wang, W., Rastinejad, F., & El‐Deiry, W. S. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1526 · Cited by 57 · see citing works
Lenglet, G., & David‐Cordonnier, M. (2010) · Journal of Nucleic Acids · doi:10.4061/2010/290935 · Cited by 50 · see citing works
Černá, V., Mrázová, B., Moserová, M., Martínek, V., Hodek, P., Hudeček, J., Frei, E., & Stiborová, M. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.06.003 · Cited by 49 · see citing works
Łuniewski, W., Wietrzyk, J., Godlewska, J., et al. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.08.032 · Cited by 49 · see citing works
Fung, S., Yang, H. Y., & Chen, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001956 · Cited by 48 · see citing works
“Such a result seems to contradict to the already known fact that neutral ellipticine is the active form to suppress the cancer cell growth [33].”
BackgroundResultEl-Readi, M. Z., Al-Abd, A. M., Althubiti, M., Almaimani, R. A., Al-Amodi, H. S. A. B., Ashour, M. L., Wink, M., & Eid, S. Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.658513 · Cited by 48 · see citing works
“Alkaloids including tetrandrine, fangchinoline, berbamine, ellipticine, cryptolepine, and neocryptolepine, terpenoids including genistein, ginsenoside, and ginseng saponin are examples of telomerase inhibitors from natural plant SM (Alberti et al., 2003; Guittat et al., 2003; Garbett and Graves, 2004; Liu et al., 2004…”
BackgroundFrausin, G., Hidalgo, A. D. F., Lima, R. B. S., et al. (2015) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2015.07.033 · Cited by 46 · see citing works
Rizza, P., PELLEGRINO, M. A., Caruso, A., et al. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.11.004 · Cited by 46 · see citing works
Synthesis, cytotoxicity, and DNA topoisomerase II inhibitory activity of benzofuroquinolinediones
Rhee, H., Park, H. J., Lee, S. K., et al. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.12.012 · Cited by 45 · see citing works
Jasenosky, L. D., Neumann, G., & Kawaoka, Y. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00138-10 · Cited by 44 · see citing works
“Doxorubicin and ellipticine appear to suppress DNA replication in eukaryotic cells through several mechanisms, including DNA intercalation and inhibition of DNA topoisomerase II activity (8, 25).”
BackgroundAdvances in the Chemistry of Natural and Semisynthetic Topoisomerase I/II Inhibitors
D'yakonov, V. A., Dzhemileva, L. U., & Dzhemilev, U. M. (2017) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63929-5.00002-4 · Cited by 44 · see citing works
DNA Intercalators and Topoisomerase Inhibitors
Avendaño, C., & Menéndez, J. C. (2008) · Elsevier eBooks · doi:10.1016/b978-0-444-52824-7.00007-x · Cited by 41 · see citing works
Stiborová, M., Poljaková, J., Martínková, E., et al. (2012) · Toxicology · doi:10.1016/j.tox.2012.08.004 · Cited by 40 · see citing works
Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives
Vann, K. R., Ergün, Y., Zencir, S., Öncüoğlu, S., Osheroff, N., & Topçu, Z. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.02.034 · Cited by 39 · see citing works
Huang, Y. S., Blower, P. E., Yang, C. H., et al. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500297 · Cited by 38 · see citing works
Stiborová, M., Indra, R., Moserová, M., et al. (2012) · Chemical Research in Toxicology · doi:10.1021/tx3000335 · Cited by 37 · see citing works
Lü, C., Wang, W., & El‐Deiry, W. S. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7461 · Cited by 37 · see citing works
Yuan, Y., Wu, Sadatmousavi, Wang, Lü, & Chen (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s31858 · Cited by 36 · see citing works
“…is usually found at higher peptide concentrations, as a result of relatively low pH ( , 5, pKa of ellipticine is about 6) in solution, 24,30 and protonated ellipticine can be stabilized by ionic interaction with the negatively charged residues (glutamic acid E in this case) of the…”
Nuclear quantum effects in a HIV/cancer inhibitor: The case of ellipticine
Sappati, S., Hassanali, A. A., Gebauer, R., et al. (2016) · The Journal of Chemical Physics · doi:10.1063/1.4968046 · Cited by 33 · see citing works
Stiborová, M., Černá, V., Moserová, M., et al. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms16010284 · Cited by 32 · see citing works
“A plant alkaloid ellipticine (5,11-dimethyl-6H-pyrido[4,3-b]carbazole, Figure 1) found in several Apocynaceae plants and its derivatives are efficient anticancer compounds that function through multiple mechanisms participating in cell cycle arrest and the initiation of apoptosis (for a summary see: [1–6]).”
BackgroundResultNovel and Efficient Synthesis of 5,8-Dimethyl-9H-carbazol-3-ol via a Hydroxydeboronation Reaction
Rault, S., Caruso, A., Voisin‐Chiret, A. S., et al. (2007) · Heterocycles · doi:10.3987/com-07-11113 · Cited by 32 · see citing works
Natural products and their role in cancer therapy
Siu, D. C. W. (2010) · Medical Oncology · doi:10.1007/s12032-010-9528-x · Cited by 31 · see citing works
“5 lg/ml Not known [25–29] Med Oncol (2011) 28:888–900 889”
BackgroundInfluentialRestoring p53 Tumor Suppressor Activity As an Anticancer Therapeutic Strategy
Martinez, J. D. (2010) · Future Oncology · doi:10.2217/fon.10.132 · Cited by 31 · see citing works
Chemical and Biological Investigation of Ochrosia elliptica Labill. Cultivated in Egypt
El‐Shiekh, R. A., Al-Mahdy, D. A., Hifnawy, M. S., et al. (2017) · Records of Natural Products · doi:10.25135/rnp.70.17.03.049 · Cited by 29 · see citing works
Kumar, N., Lal, N., Nemaysh, V., & Luthra, P. M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103911 · Cited by 29 · see citing works
Update on novel synthetic approaches towards the construction of carbazole nuclei: a review
Munawar, S., Zahoor, A. F., Mansha, A., Bokhari, T. H., & Irfan, A. (2024) · RSC Advances · doi:10.1039/d3ra07270c · Cited by 28 · see citing works
“The carbazole derivatives have emerged to nd anti-cancerous activities against such onc-ogens, i.e. , ellipticine 11 , 39 a promising anti-tumor drug.”
BackgroundMethodZeniou, M., Fève, M., Mameri, S., Dong, J., Salomé, C., Chen, W., El-Habr, E. A., Fanny, B., Sy, M., Obszynski, J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0134793 · Cited by 28 · see citing works
“Besides its intercalating properties and inhibition of topoisomerase II, ellipticine and derivatives act on a variety of targets [45–49].”
BackgroundSynthesis and biological activity of 5-aza-ellipticine derivatives
Moody, D. L., Dyba, M. D., Kosakowska‐Cholody, T., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.093 · Cited by 28 · see citing works
Sunke, R., Kumar, V., Ashfaq, M. A., et al. (2015) · RSC Advances · doi:10.1039/c5ra06764b · Cited by 27 · see citing works
DNA INTERCALATORS AND USING THEM AS ANTICANCER DRUGS
Goftar, M. K., Kor, N. M., & Kor, Z. M. (2014) · Cited by 26 · see citing works
Self-assembling Peptides in Current Nanomedicine: Versatile Nanomaterials for Drug Delivery
Peng, F., Zhang, W., & Qiu, F. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190712154021 · Cited by 26 · see citing works
Hraběta, J., Groh, T., Khalil, M. A., Poljaková, J., Adam, V., Kizek, R., Uhlı́k, J., Doktorová, H., Černá, T., Frei, E., et al. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3066 · Cited by 24 · see citing works
Lee, H., Chen, G. S., Chen, C., et al. (2010) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.319 · Cited by 23 · see citing works
Mori, R., Kato, A., Komenoi, K., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.05.032 · Cited by 23 · see citing works
Synthesis of functionalized ellipticinium and ellipticine derivatives via electrophilic cyclization
Chaitanya, T. K., & Nagarajan, R. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c1ob05258f · Cited by 23 · see citing works
Černá, T., Hraběta, J., Eckschlager, T., Frei, E., Schmeiser, H. H., Arlt, V. M., & Stiborová, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010164 · Cited by 21 · see citing works
Paul, S., Mallick, A., & Majumdar, T. (2015) · Chemical Physics Letters · doi:10.1016/j.cplett.2015.05.051 · Cited by 22 · see citing works
Russell, E. G., Guo, J., O’Sullivan, E. C., O’Driscoll, C. M., McCarthy, F. O., & Cotter, T. G. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0302-y · Cited by 21 · see citing works
“Although ellipticines display a lack of hematological toxicity [35], they still caused unexpected toxic side effects [36].”
BackgroundDan, V. M., Varghese, T. S., Viswanathan, G., & Baby, S. (2019) · Current Cancer Drug Targets · doi:10.2174/1568009619666190927150131 · Cited by 18 · see citing works
Synthesis and Antiproliferative Activity of Some Ellipticine‐Like 11H‐Pyrido[a]carbazole Derivatives
Ferlin, M. G., Gia, O. M., & Via, L. D. (2011) · ChemMedChem · doi:10.1002/cmdc.201100233 · Cited by 18 · see citing works
Tian, L., Li, X., Tang, X., Zhou, X., Luo, L., Ma, X., Tang, W., Yu, J., Ma, W., Yang, X. Y., et al. (2019) · Inflammation · doi:10.1007/s10753-019-01112-z · Cited by 18 · see citing works
Emerging Targets in the Bioactivity of Ellipticines and Derivatives
O’Sullivan, E. C., Miller, C. M., Deane, F. M., & McCarthy, F. O. (2013) · Studies in natural products chemistry · doi:10.1016/b978-0-444-62615-8.00006-0 · Cited by 17 · see citing works
Ryvolová, M., Adam, V., Eckschlager, T., et al. (2012) · Electrophoresis · doi:10.1002/elps.201200056 · Cited by 17 · see citing works
Stiborová, M., Indra, R., Frei, E., Kopečková, K., Schmeiser, H. H., Eckschlager, T., Adam, V., Heger, Z., Arlt, V. M., & Martínek, V. (2017) · Monatshefte für Chemie - Chemical Monthly · doi:10.1007/s00706-017-1986-9 · Cited by 16 · see citing works
Indra, R., Černá, T., Heger, Z., et al. (2019) · Toxicology · doi:10.1016/j.tox.2019.03.009 · Cited by 16 · see citing works
Pourhossein, A., Rafizadeh, M., & Chen, P. (2020) · Polymers for Advanced Technologies · doi:10.1002/pat.4924 · Cited by 16 · see citing works
Basset, J., Romero, M., Serra, T., et al. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.10.022 · Cited by 15 · see citing works
Zsila, F., Kámán, J., Bogányi, B., et al. (2011) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob01221a · Cited by 15 · see citing works
Chaitanya, T. K., Prakash, K. S., & Nagarajan, R. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.06.076 · Cited by 13 · see citing works
Deane, F. M., Miller, C. M., Maguire, A. R., et al. (2011) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.598 · Cited by 13 · see citing works
Stimulation of Suicidal Erythrocyte Death by Ellipticine
Calabrò, S., Alzoubi, K., Bissinger, R., Faggio, C., & Lang, F. J. W. (2014) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12350 · Cited by 12 · see citing works
Anticancer and Immunomodulatory Activities of a Novel Water-Soluble Derivative of Ellipticine
de Oliveira, R. C., Pontes, G. S., Kostyuk, A., Camargo, G. B. C., Dhyani, A., Shvydenko, T. I., Shvydenko, K. V., & Grafov, A. (2020) · Molecules · doi:10.3390/molecules25092130 · Cited by 12 · see citing works
Sassano, M. F., Schlesinger, A. P., & Jarstfer, M. B. (2012) · The Open Medicinal Chemistry Journal · doi:10.2174/1874104501206010020 · Cited by 11 · see citing works
Zsila, F. (2015) · RSC Advances · doi:10.1039/c5ra23437a · Cited by 11 · see citing works
Groh, T., Hraběta, J., Poljaková, J., et al. (2012) · PubMed · Cited by 11 · see citing works
Li, W., Whiteway, M., Hang, S., Yu, J., Lu, H., & Jiang, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-62131-z · Cited by 13 · see citing works
“This outcome may be attributed to the inadequate pharmacokinetic parameters of ellipticine 52 , which likely hinder its ef fi cacy in enhancing the antifungal action of FLC in this context.”
Das, A., Thakur, R., & Chakraborty, A. (2013) · RSC Advances · doi:10.1039/c3ra43037e · Cited by 10 · see citing works
Ellipticine induces apoptosis in T-cell lymphoma via oxidative DNA damage
Savorani, C., Manfé, V., Biskup, E., & Gniadecki, R. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.929673 · Cited by 10 · see citing works
Stiborová, M., Poljaková, J., Mrízová, I., et al. (2014) · International Journal of Electrochemical Science · doi:10.1016/s1452-3981(23)08197-x · Cited by 10 · see citing works
Anticancer Tetrahydrocarbazoles: A Wide Journey from 2000 Till Date
Kumar, N., & Gupta, P. (2022) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666221028163319 · Cited by 9 · see citing works
Konakahara, T., Sato, N., Kawai, Y., Akaba, Y., Honma, S., & Sakai, N. (2016) · Heterocycles · doi:10.3987/com-16-13404 · Cited by 9 · see citing works
Recent synthesis of ellipticine and its derivatives
Ibrahim‐Ouali, M., & Dumur, F. (2018) · ARKIVOC · doi:10.24820/ark.5550190.p010.445 · Cited by 9 · see citing works
Chu, D., Xu, W., Ran, P., & Chen, P. (2015) · RSC Advances · doi:10.1039/c4ra14827d · Cited by 8 · see citing works
Fischer Reaction in the Synthesis of New Triterpene Indoles of the Fusidane Series
Salimova, E. V., & Parfenova, L. V. (2022) · Russian Journal of Organic Chemistry · doi:10.1134/s1070428022010031 · Cited by 8 · see citing works
Wang, H., Yang, L., & Rempel, G. L. (2013) · Macromolecular Bioscience · doi:10.1002/mabi.201300333 · Cited by 8 · see citing works
Advances in heterocycles as DNA intercalating cancer drugs
Das, A., & Banik, B. K. (2022) · Physical Sciences Reviews · doi:10.1515/psr-2021-0065 · Cited by 7 · see citing works
Formation of DNA Adducts by Ellipticine and Its Micellar Form in Rats — A Comparative Study
Stiborová, M., Manhartova, Z., Hodek, P., Adam, V., Kizek, R., & Frei, E. (2014) · Sensors · doi:10.3390/s141222982 · Cited by 7 · see citing works
“Ellipticine (5,11-dimethyl-6H-pyrido(4,3-b)carbazole) and its derivatives are efficient anticancer compounds that function through multiple mechanisms participating in cell cycle arrest and initiation of apoptosis (for a summary see [1–6]).”
BackgroundVranová, I., Moserová, M., Hodek, P., et al. (2013) · International Journal of Electrochemical Science · doi:10.1016/s1452-3981(23)14249-0 · Cited by 7 · see citing works
Shimazu, A., Kawagoshi, M., Takeda, S., et al. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.12.031 · Cited by 7 · see citing works
Reig, M., Bosque, R., Font‐Bardía, M., et al. (2018) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2018.03.008 · Cited by 7 · see citing works
Zsila, F., & Samsonov, S. A. (2018) · Carbohydrate Research · doi:10.1016/j.carres.2018.03.014 · Cited by 7 · see citing works
El‐Saadony, M. T., Alkafaas, S. S., Saad, A. M., et al. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03720-2 · Cited by 6 · see citing works
Kuskucu, M., Akyildiz, V., Kulmány, Á. E., et al. (2019) · Medicinal Chemistry Research · doi:10.1007/s00044-019-02472-9 · Cited by 6 · see citing works
Bioactive properties of native Australian medicinal plants.
Jones, G. L., Smith, J. E., Watson, K., Acharya, S. N., & Thomas, J. E. (2007) · EPubDev Repository · Cited by 6 · see citing works
Pharmacokinetics of Peptide Mediated Delivery of Anticancer Drug Ellipticine
Ma, W., Lu, S., Pan, P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043684 · Cited by 6 · see citing works
“It can inhibit osteolytic and breast cancer metastases, kidney cancer, brain tumor and acute myeloblastic leukemia [9–10].”
BackgroundAn amphipathic lytic peptide for enhanced and selective delivery of ellipticine
Lu, S., Ding, Y., Wu, Y. F., et al. (2016) · Journal of Materials Chemistry B · doi:10.1039/c6tb00529b · Cited by 6 · see citing works
Dimeric binding of plant alkaloid ellipticine to human serum proteins
Zsila, F., & Beke‐Somfai, T. (2016) · RSC Advances · doi:10.1039/c6ra06078a · Cited by 6 · see citing works
- Authors
- Garbett, N., & Graves, D.
- Affiliations
- University of Alabama at Birmingham (US)
- Venue
- Current Medicinal Chemistry-Anti-Cancer Agents
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2004-03-01
- Volume
- 4
- Issue
- 2
- Pages
- 149-172
- ISSN
- 1568-0118 (ISSN-L)
- OpenAlex
- W2077301074
- Cited by
- 137
- References
- 0
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 3 · 2023: 2 · 2022: 8 · 2021: 2 · 2020: 5 · 2019: 10 · 2018: 7 · 2017: 4 · 2016: 9 · 2015: 11 · 2014: 7 · 2013: 9 · 2012: 9
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Anti-Cancer Agents in Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Chemistry › Organic Chemistry › Synthesis and bioactivity of alkaloids
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Keywords
- ellipticine, DNA intercalation, anticancer agents, Apocynaceae, topoisomerase II, telomerase, rational drug design, hybrid molecules, membrane permeability, drug toxicity, mechanism of action
- MeSH terms
- Animals, Antineoplastic Agents, Ellipticines, Humans, Phytotherapy, Neoplasms, Structure-Activity Relationship, Apocynaceae
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review